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Seasonal  inﬂuenza  places  a  major  burden  on  public  health.  Consequently,  the  World  Health  Organization
(WHO)  and  over 40%  of  national  governments  recommend  vaccination  of at-risk  groups.  However,  no
systematic  global  data  are  available  to assess  vaccine  provision  nor  the  effect  of  immunization  policies.
To  address  this  situation,  IFPMA  IVS  surveyed  global  vaccine  supply,  covering  157 countries  from  2004
to  2009.  The  study  also  used  UN data  and  a novel  vaccine  provision  “hurdle”  rate  (set  at  15.9% of the
population,  based  on  WHO  immunization  recommendations  for  the  elderly)  to  compare  vaccine  supply
with  development  status.  In a sub-group  of  26  countries,  the level of  vaccine  provision  was  also  correlated
to  the presence/absence  of  speciﬁc  vaccination  policies.
Between 2004  and  2009,  global  annual  vaccine  provision  increased  72%  to  449 million  doses.  Europe
and  the  Americas  accounted  for  75% to  80%  of  the  total  each  year, with  several  countries  in these  regions,  as
well  as  China,  Japan  and  Thailand,  achieving  notable  increases  during  the  study  period.  However,  despite
the  global  growth,  only  20%  of  countries  reached  the  study’s  modest  “hurdle”  rate.  On  a per capita  basis,
dose  distribution  did  not  correlate  directly  with  income,  and  several  less  developed  countries,  particu-
larly  in  Latin  America,  outperformed  more  developed  nations  (notably  in Eastern  and  Southern  Europe).
In  the sub-group  analysis,  the  presence  of  ofﬁcial  public  health  authority  vaccination  recommendations
did  not  correlate  well  with  higher  vaccine  supply  (positive:negative  correlation  =  1.3:1), while  reimburse-
ment  (4.5:1)  and the  use  of  wide-scale  communication  activities  (5.3:1)  correlated  more  strongly  than
development  status  (2.7:1).
This study  shows  that globally  vaccination  levels  remain  low,  and  ofﬁcial  vaccination  recommendations
alone  are  insufﬁcient  to drive  higher  coverage.  Rather,  policy  measures  that  directly  impact  patients
(i.e.  reimbursement  and  communication)  appear  more  effective,  irrespective  of  countries’  development
status,  and  therefore  may  do more  to  help  protect  local  populations  against  inﬂuenza.. Introduction
While much recent scientiﬁc and media attention has focused
n pandemic inﬂuenza, it remains the case that seasonal inﬂuenza
pidemics represent a major and ongoing threat to public
ealth. WHO  estimates that seasonal inﬂuenza is responsible for
,000,000–5,000,000 cases of severe illness and 250,000–500,000
eaths each year [1]. In 2003, the World Health Assembly
WHA) stated, in its resolution on the prevention and control of
nﬂuenza, that seasonal epidemics cause fatal complications in up
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to 1,000,000 people annually [2]. As a result, WHO  and its mem-
ber countries recognize the role that immunization can play in
preventing and reducing this burden, and recommend vaccination
for those at risk, in particular the elderly and those with chronic
illnesses [1,2]. This position is mirrored by the public health poli-
cies of many governments [3], with more than 40% of the world’s
countries including seasonal inﬂuenza vaccination in their national
immunization schedules [4].
Recognizing that “many of these deaths could be prevented
through increased use, particularly in people at high risk, of exist-
ing vaccines, which are safe and highly effective”, the 2003 WHA
resolution set a target for those countries with inﬂuenza vaccina-
tion policies. This called for an increase in vaccine coverage for all
people at high risk, and in particular the immunization of at least
Open access under CC BY-NC-ND license.50% of the elderly by 2006, rising to 75% by 2010 [2]. However,
despite this consensus on the need to increase vaccination rates,
systematic worldwide data have not been available to assist pub-
lic health authorities to monitor vaccine uptake, review progress
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owards these targets and assess the impact of immunization poli-
ies. Although a number of individual countries monitor vaccine
sage locally, and the Macroepidemiology of Inﬂuenza Vaccination
tudy group previously mapped vaccine provision in 56 countries
rom 1997 to 2003 [5], no formal mechanism is in place to provide
ngoing information on a regional or worldwide basis.
To  help address this situation, in 2008 the International Feder-
tion of Pharmaceutical Manufacturers and Associations Inﬂuenza
accine Supply task force (IFPMA IVS) developed a survey method-
logy to assess inﬂuenza vaccine provision globally, and reported
op line results covering 141 countries from 2004 to 2007 [6]. In
010, IFPMA IVS updated and extended this database. The result-
ng dataset now offers policy makers a unique resource, providing
nsights into the distribution of seasonal inﬂuenza vaccine in 157
ountries for the 6-year period from 2004 to 2009. To increase the
tility of this information, IFPMA IVS collected data on a range of
mmunization policies from a sub-group of countries and assessed
hese alongside national vaccine provision data, to identify mea-
ures that have the potential to improve vaccination coverage.
.  Materials and methods
.1.  Vaccine dose distribution
In  2010, IFPMA IVS issued a previously developed retrospective
urvey [6] to its member companies, which collectively man-
facture and supply the vast majority of the world’s seasonal
nd pandemic inﬂuenza vaccines (IFPMA IVS member companies:
bbott Biologicals, Baxter, Biken, Crucell, CSL, Denka Seiken, Glaxo-
mithKline Biologicals, Green Cross, Kaketsuken, Kitasato Institute,
edImmune, Novartis Vaccines, sanoﬁ pasteur, sanoﬁ pasteur MSD
nd Sinovac). The survey requested information on the supply of
easonal trivalent inﬂuenza vaccine doses during 2008 and 2009
o all WHO  Member States. As the study aimed to quantify vac-
ine provision to both the northern and southern hemispheres, the
upply period was deﬁned by calendar year rather than inﬂuenza
eason.
To ensure compliance with competition regulations, the sur-
ey results were collected and aggregated by an independent
hird-party legal counsel. The resulting anonymized database was
hen combined with the results of the previous IFPMA IVS survey
2004–2007), which had been compiled using a similar methodol-
gy. Countries for which there was no supply throughout the entire
urvey period were excluded from the study.
.2. Dose distribution in relation to population and income
To  assess vaccine provision in relation to each country’s pop-
lation size, and relative to per capita income, the study utilized
opulation and gross national income (GNI) data from the United
ations’ (UN) statistics database [7]. As 2009 data were unavailable
t the time of analysis, extrapolations were made from 2008 infor-
ation. Three countries (Afghanistan, Iraq and Wallis and Futuna)
ere excluded from population-based analyses because up-to-date
nformation was not available.
.3.  Dose distribution in relation to development status
To  assess each country’s vaccine provision in the context of its
evelopment status, the study adopted classiﬁcations used by the
N Department of Economic and Social Affairs Population Division
8; page xii]. Consequently, countries were considered as either
more developed” or “less developed” according to their UN desig-
ation.2011) 9459– 9466
2.4. Dose distribution “hurdle” rate
To compare vaccine supply with development status, the study
used a conservative “hurdle” rate to deﬁne “higher” and “lower”
vaccine provision. This “hurdle” was derived from WHO  vaccina-
tion recommendations [3] to ensure global applicability, and was
based on the single major recommended group for which global
epidemiological data are available: the elderly aged ≥65 years. As
the WHO  recommendations were “based on data from industrial-
ized countries” [3], the “hurdle” rate was  deﬁned by the authors
as the number of doses required to immunize those aged 65 years
or older in more developed nations. UN epidemiological data [8]
indicated that this group comprised 15.9% of the population at the
time of the study analysis, equating to a “hurdle” rate of 159 doses
per 1000 population.
2.5.  Impact of vaccination policies
To assess the potential effect of selected immunization poli-
cies on vaccine provision, the study collected information on local
guidelines and vaccination practices in a sub-group of 26 countries.
These were selected to include at least one country from each WHO
and UN region, to provide a balance between more developed and
less developed countries, and to enable reliable data collection from
countries where information was  available.
The presence (or absence) of the following individual policies
was recorded, using the criteria speciﬁed:
• Recommended = inclusion of the elderly and those with chronic
conditions (pulmonary, cardiovascular and metabolic) in local
vaccination  guidelines.
• Reimbursed = funding available for vaccines and/or administra-
tion  for the above risk groups.
• Communicated  = wide-scale communication activities under-
taken.
Each  of these policies, along with development status, were
then compared with vaccine provision to determine the level of
correlation. Correlations were based on the expected impact of
each of these different factors. Therefore, in countries with vaccine
distribution ≥159 doses per 1000 population, correlations were
considered positive when vaccination was  supported by (1) rec-
ommendations, (2) reimbursement or communication activities,
or (3) the country was  more developed. Similarly, where vaccine
distribution was  <159 doses per 1000 population, the absence of
(1) recommendations, (2) reimbursement, (3) communications, or
(4) lower development status, were also taken as positive corre-
lations. Where these conditions were not met, correlations were
considered negative.
The  total number of correlations was  then calculated across
all 26 sub-group countries for each policy measure (and develop-
ment level). These were expressed as a ratio of positive-to-negative
correlations, to provide an “inﬂuence factor” for each vaccination
policy and development status.
3. Results
3.1. Global and regional dose distribution
The study found that seasonal inﬂuenza vaccine was  supplied
to 157 WHO  Member States at some time during the survey
period (2004–2009). This was an 11% increase on the 141 countries
reported in the earlier IFPMA IVS study covering 2004–2007 [6].
Global vaccine distribution increased throughout the 6-year study
period, although the rate of growth slowed substantially during the
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ast two years (Fig. 1). Total worldwide distribution increased 72%
rom 262 million doses in 2004 to 449 million in 2009.
On  a regional basis, distribution increased in each of the six WHO
egions (Fig. 2), although the growth was not uniform. Notably,
urope and the Americas received the majority of vaccine distri-
ution throughout the period. Together, these regions consistently
ccounted for 75%–80% of global supply, despite growth elsewhere
nd a drop in vaccine provision in the Americas following a peak
n 2007. Of the remaining vaccine supply, the Western Paciﬁc
egion received the vast majority, with the combined African, East-
rn Mediterranean, and South–East Asian regions accounting for
etween 1% and 4% of global distribution each year.
.2.  National dose distribution
Between  the beginning and the end of the surveyed period, vac-
ine provision grew in over 70% of the 157 study countries. Notable
ncreases took place in Europe (in France, Germany, Italy, the
etherlands, Spain and the UK), the Americas (in Brazil, Colombia,
exico and the USA) and, elsewhere, in China, Japan and Thailand
Fig. 3). However growth was non-uniform. Only four of these
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countries (Mexico, Spain, Thailand and the UK) achieved year-on-
year increases from 2004 to 2009, while dose distribution in the US
peaked in 2007 and subsequently decreased 23% in the following 2
years.
Dose distribution fell in a number of countries, although the
declines were less marked than the growth in other nations. The
most notable decrease occurred in the Republic of Korea, where
distribution fell 27% during the study period, from over 16.5 million
doses in 2004 to approximately 12 million in 2009.
Analysis of per capita dose distribution data shows that, despite
growth at the global, regional and national levels, no country dis-
tributed sufﬁcient vaccines for half of its population and only 20%
of WHO  Member States reached the conservative study “hurdle”
rate of 159 doses per 1000 population (Fig. 4). Over two-thirds of
countries did not distribute sufﬁcient doses to cover 10% of their
populations, while more than one-third distributed too few doses
to protect even 1% of inhabitants.3.3.  Per capita dose distribution versus GNI
Population-based comparisons show that vaccine supply and
national income do not correlate directly (Fig. 5). Overall, 46
USAJapanBrazilGermanyMexicoFrance
n countries with notable growth (2004–2009).
9462 A. Palache / Vaccine 29 (2011) 9459– 9466
0 50   100  150  200 250  300  350  400  450  500 
Doses  distributed pe r 1,000 populati on 
Luxembourg
Netherlands
Malta
Qatar
U.S.A.
France
Japan
Spain
Canada
Italy
Finland
United Kingdom
Greece
Germany
Australia
Belgium
Denmark
Chile
Portugal
Republic of Korea
Ireland
Panama
New Zealand
Switzerland
Mexico
Colombia
Sweden
Oman
Israel
Iceland
Hong Kong (China)
Cyprus
Austria
Slovakia
Brazil
Norway
Kuwait
Bahrain
El Salvador
Peru
Uruguay
Slovenia
Costa Rica
Venezuela
Lebanon
Czech Republic
Singapore
New Caledonia
Croatia
French Polynesia
Paraguay
Argentina
Cuba
Macao(China)
Poland
Lithuania
Montenegro
Belize
Saudi Arabia
Bolivia
Bulgaria
Nicaragua
Thailand
Dominica
Serbia
St. Vincent & The Grenadines
Honduras
Algeria
Mauritius
Kazakhstan
Guyana
Ecuador
Belarus
Tunisia
Bosnia & Herzegovinia
Bahamas
Iran
Turkey
Barbados
Estonia
Russian Federation
Romania
Jordan
Libyan  Arab Jamahiriya
Albania
United  Arab Emirates
Guatemala
Malaysia
Grenada
South Africa
Hungary
Philippines
Latvia
Suriname
Morocco
Egypt
Trinidad & Tobago
Dominican Republic
Uzbekistan
St. Lucia
Brunei Darussalam
China
Ukraine
Antigua & Barbuda
TFYR of Macedonia
Armenia
Namibia
Jamaica
Vietnam
Azerbaijan
Syrian Arab Republic
Botswana
Republic of Moldova
Kyrgyzstan
Georgia
Turkmenistan
Indonesia
Mongolia
Pakistan
Tajikistan
Fiji
Sudan
Mali
Lao People’s Democ. Rep.
Cambodia
India
Haiti
Cameroon
Côte d’Ivoire
Benin
Cape Verde
Bangladesh
Myanmar
Angola
Nepal
Yemen
Burkina Faso
Zimbabwe
Zambia
Kenya
hurdle rate o f
159 dose s per 1,000 populati on
Fig. 4. Worldwide seasonal inﬂuenza vaccine dose distribution per 1000 population (2009).
A. Palache / Vaccine 29 (2011) 9459– 9466 9463
110,000 100,00 0 90,00 0 80,00 0 70,00 0 60,00 0 50,00 0 40,000 30,000 20,000 10,00 0 0
GNI pe r capita (US $)
0 50 10 0 15 0 20 0 25 0 30 0 35 0 40 0 45 0 50 0
Doses distri but ed per 1, 000 p opulat ion
hurdle rate  of
159 doses per  1, 000 popul ati on
Norway
Qatar
Luxembourg
United Arab Emirates
Kuwait
Denmark
Switzerland
Sweden
Netherlands
Ireland
Finland
Austria
Belgium
Australia
Macao(China)
Canada
Germany
France
U.S.A.
United Kingdom
Singapore
Brunei Darussalam
New Caledonia
Japan
Italy
Spain
Hong Kong (China)
Iceland
Greece
New Zealand
Cyprus
Israel
Bahrain
Slovenia
Portugal
Bahamas
Czech Republic
French Polynesia
Malta
Saudi Arabia
Republic of Korea
Oman
Slovakia
Trinidad & Tobago
Estonia
Latvia
Libyan  Arab Jamahiriya
Croatia
Lithuania
Hungary
Poland
Barbados
Antigua & Barbuda
Russian Federation
Venezuela
Romania
Turkey
Uruguay
Mexico
Chile
Brazil
Argentina
Kazakhstan
Montenegro
Malaysia
Mauritius
Serbia
Bulgaria
Lebanon
Belarus
Costa Rica
Panama
St. Lucia
Grenada
Suriname
Cuba
Colombia
Botswana
Bosnia & Herzegovinia
St. Vincent &  The Grenadines
Jamaica
South Africa
Azerbaijan
Algeria
Iran
Dominica
Dominican Republic
TFYR of Macedonia
Albania
Peru
Ukraine
Thailand
Armenia
Belize
Namibia
Fiji
Ecuador
Tunisia
Jordan
El Salvador
Cape Verde
China
Georgia
Paraguay
Guatemala
Morocco
Syrian Arab Republic
Indonesia
Mongolia
Philippines
Egypt
Republic of Moldova
Honduras
Sudan
Angola
Turkmenistan
Bolivia
Guyana
Yemen
Cameroon
Nicaragua
Côte d’Ivoire
Zambia
India
Vietnam
Pakistan
Uzbekistan
Kyrgyzstan
Lao People’s Democ. Rep.
Kenya
Benin
Cambodia
Haiti
Mali
Myanmar
Bangladesh
Burkina Faso
Nepal
Tajikistan
Zimbabwe
Fig. 5. Per capita gross national income versus seasonal inﬂuenza vaccine dose distribution per 1000 population (2009).
9464 A. Palache / Vaccine 29 (2011) 9459– 9466
Table  1
Vaccination policies, development status and vaccine provision by country.
Country Immunization policies Development statusd Vaccine dose distributione
Recommendeda Reimbursedb Communicatedc
Australia Yes Yes Yes More Higher
Austria  Yes No No More Lower
Brazil Yes Yes Yes Less Lower
Canada Yes Yes Yes More Higher
Chile Yes Yes Yes Less Higher
China  Yes No Yes Less Lower
Croatia  Yes Yes – More Lower
Egypt  No – – Less Lower
Germany Yes Yes Yes More Higher
Indonesia f No No Less Lower
Italy Yes Yes Yes More Higher
Japan  Yes Yes – More Higher
Korea  (Republic of) Yes g Yes Less Higher
Malta  Yes – – More Higher
Mexico  Yes Yes Yes Less Higher
New  Zealand Yes Yes Yes More Higher
Norway  Yes – – More Lower
Philippines  Yes No – Less Lower
Poland Yes No No More Lower
Singapore  Yes No Yes Less Lower
South  Africa Yes No No Less Lower
Sweden  Yes Yes Yes More Higher
Thailand  Yes Yes No Less Lower
Turkey  Yes Yes – Less Lower
United  Kingdom Yes Yes Yes More Higher
US Yes Yes Yes More Higher
a Recommended for elderly and chronic illnesses.
b Reimbursement for elderly and chronic illnesses.
c Broad communication.
d UN designation.
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manufactured by non-IFPMA IVS members [9]).
The study also provides a systematic assessment of the potential
effect of development status and immunization policies on vac-
cine provision (with more developed and less developed nations
Table 2
Correlations between vaccine provision and immunization policies and develop-
ment  status in 26 countries.
Correlation with vaccine dose distribution
Positive:negative “Inﬂuence factor”
Immunization policiese Versus study “hurdle” rate.
f Recommended for elderly; not for chronic illness.
g Reimbursement for elderly; not for chronic illness.
ountries were more developed and 108 were less developed.
wenty-two of 46 more developed countries (48%) achieved vac-
ine provision >159 doses/1000 population and nine of 108 less
eveloped countries (8%) reached this level. Therefore, of the 31
ountries with vaccine provision ≥159 doses per 1000 popula-
ion, 29% (nine countries) were less developed. Four of these nine
ountries were in Latin America. Of the 123 countries with vac-
ine provision <159 doses per 1000 population, 20% (24 countries)
ere more developed, of which most were located in Eastern and
outhern Europe.
.4.  Impact of vaccination policies
The study collected information on vaccine recommendations,
nd reimbursement and communication policies from 26 coun-
ries (Table 1). Exactly half of these had vaccine provision levels
bove the study “hurdle” rate (2009 data), and 12 (46%) were clas-
iﬁed as less developed by the UN. Almost all the countries (92%)
ecommended vaccination for two key risk groups in the WHO
uidance [3]: the elderly above a deﬁned age and those with chronic
onditions. In approximately two-thirds of the countries (65%)
eimbursement was available for both of these risk groups, and in
early three-quarters (74%) wide-scale communication activities
ere undertaken.
When assessed across all 26 countries (Table 2), the existence of
ocal vaccination recommendations did not correlate well with the
evel of vaccine provision (positive:negative correlation = 1.3:1).
evelopment status correlated to some extent (2.7:1), but vaccine
upply correlated most strongly with reimbursement (4.5:1) and
ommunication (5.3:1). Across the sub-group countries, these two
olicy implementation measures correlated 3.5–4.1 times morestrongly  with vaccine provision than the presence of an immuniza-
tion policy alone.
4.  Discussion
This study provides a unique insight into worldwide seasonal
inﬂuenza vaccine usage. Although the adopted endpoint, dose
distribution, may  overestimate vaccine use to an extent (due to
wastage and unused returns) it represents a useful surrogate.
Unlike vaccine usage data that is collected in a limited number of
countries using different methodologies, this study’s results were
compiled uniformly on a global basis from a standardized source:
the vaccine producers that manufacture the majority of the world’s
inﬂuenza vaccines (IFPMA IVS members accounted for approx-
imately three-quarters of the global seasonal inﬂuenza vaccine
production reported by a 2010 WHO  survey, with the remainderRecommended 14:11 1.3:1
Reimbursed 18:4 4.5:1
Communicated 16:3 5.3:1
Development status 19:7 2.7:1
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vaccine distribution.
Robust  local seasonal demand is acknowledged to be an impor-
tant factor in sustaining production capacity [2]. It is notable thatA. Palache / Vaccin
hown on a single chart). This was possible through the use of a
ovel vaccine supply “hurdle” rate, which was based on a key WHO
ecommended risk group (the elderly). While this threshold was
erived from data from more developed nations, it was deemed
pplicable in less developed countries also, because although a
maller proportion of the population of these countries was  aged
65 years old [8], WHO  recommendations state that “the appro-
riate age for general vaccination may  be considerably lower in
ountries with poor living conditions” [3], thereby offsetting the
ffect of demographic differences. Notwithstanding the utility of
his “hurdle” rate, its exclusion of other important inﬂuenza risk
roups, such as those with chronic illnesses, means it must be con-
idered a conservative threshold against which to judge vaccine
upply. To allow a comparison of the effect of different policies
cross a disparate group of countries, the study utilized prag-
atic deﬁnitions of reimbursement and communication activities
o reﬂect the greatly varying health systems, infrastructure and
upport available in the different nations.
The study’s assessment of the effect of immunization policies
s the ﬁrst time that this methodology has been applied to such
 diverse group of countries. Although the sub-group of countries
as not fully representative of each WHO  region, it was  balanced
etween more and less developed nations and lower versus higher
accine distribution. In addition, the threshold for the presence of
ocal policies was set at a higher level than the conservative “hur-
le” for vaccine provision, in order to detect genuine impacts on
ose distribution (i.e. recommendation and reimbursement cri-
eria included both the elderly and those with chronic diseases).
onsequently, the study offers an important insight into the rela-
ive success of speciﬁc vaccination policies and provides consistent
esults from a highly disparate group of countries selected from
ach region of the world.
.  Conclusions
The study found steady year-on-year growth in the global use of
easonal inﬂuenza vaccine, albeit from a low base. Encouragingly,
he study identiﬁed policies that have the potential to continue this
ositive trend. While recommending vaccination alone does not
ppear sufﬁcient to encourage high levels of vaccine uptake, the
se of reimbursement and communication policies that directly
onnect with patients may  improve countries’ vaccination rates,
rrespective of their development status. Increasing seasonal vac-
ine coverage remains an important objective, both to help protect
gainst annual epidemics and to enhance global capabilities to com-
at future inﬂuenza pandemics.
.1. Vaccination rates remain below recommended levels
The  beneﬁts of seasonal inﬂuenza vaccination are widely rec-
gnized, and 79 WHO  Member States include the vaccine in their
ational immunization schedules [4]. Of these countries, 56 (71%)
re in the Americas and Europe [4], which together accounted for
5%–80% of dose distribution in the present study. However, even
n these countries, recommendations were not fully implemented
nd immunization rates remained relatively low. For example, the
urrent study shows that, in 2009, the USA distributed sufﬁcient
accine for 36% of its population, although its Advisory Commit-
ee on Immunization Practices recommended that approximately
5% should be vaccinated [10]. In Europe, vaccination recommen-
ations covered up to 49% of the population of EU-25 countries
11], however not one of the countries distributed sufﬁcient vac-
ine to achieve this, and 11 of the 25 countries did not distribute
nough to reach half this level. Across all WHO  Member States, only
0% reached the study’s conservative “hurdle” rate. As a result, this2011) 9459– 9466 9465
situation  may  encourage countries to redouble their efforts to meet
the WHA  target of immunizing at least 75% of the elderly [2].
5.2.  Policies can inﬂuence vaccine uptake
The current study shows that vaccine use does not correlate
directly with national wealth, and a number of less developed coun-
tries outperformed richer nations. The global data shows that this
was particularly notable amongst Latin American countries, where
several had vaccine provision above the study “hurdle” rate, while
a number of Eastern and Southern European countries had lower
levels of vaccine use, despite their more developed status.
The  sub-group analysis shows that a range of policy mea-
sures can inﬂuence immunization rates. The strongest correlation
occurred with policies that have a direct connection with patients:
reimbursement and communication. These appear more important
than development status, while ofﬁcial public health authority vac-
cination recommendations alone appear to have little or no effect,
but rather may  be a necessary characteristic for greater vaccine use
as they were present in all sub-group countries that achieved higher
levels of provision. These ﬁndings mirror those from earlier work in
Europe, which concluded that improving vaccine coverage requires
public communication/education campaigns and funding for vac-
cination, alongside health care workers proactively recommending
immunization to at-risk patients [12].
5.3. Relationship between seasonal vaccine distribution and
pandemic  preparedness
The  use of seasonal inﬂuenza vaccines not only helps protect
against epidemics, but provides the foundations of pandemic pre-
paredness [2]. Annual seasonal vaccine use sustains production
capacity, and therefore dictates the global capability to respond
during a pandemic. However, despite the growth in seasonal
inﬂuenza vaccine use during the study period, uptake continues
to be substantially lower than production capacity. A study by the
international consultancy Oliver Wyman  [13] estimated that global
seasonal manufacturing capacity stood at more than double the
449 million doses distributed by IFPMA IVS members in 2009, and
was at least 50% greater than the WHO  estimate of total worldwide
production [9]. The consultancy predicted that within ﬁve years,
capacity will increase to more than three times the highest level of
vaccine provision achieved in the present study.
Consequently, accelerating the growth in seasonal inﬂuenza
vaccine use remains an important public health objective. This
study shows that proactive vaccination policies provide an oppor-
tunity for many countries to achieve this, not just the most afﬂuent.
Indeed, of the nine countries in the sub-group analysis with notable
increases in vaccine use (Brazil, China, Germany, Italy, Japan,
Mexico, Thailand, UK, USA) all but one had reimbursement policies
in place, and similarly all but one undertook broad communication
activities, although four (46%) were classiﬁed as “less developed”.
Similarly, of the three Latin American countries included in the
sub-group, all were “less developed” but all had introduced reim-
bursement policies and conducted broad communications, and two
of the three (Chile and Mexico) achieved the study hurdle rate formany of the countries with major increases in usage during the
study period either have vaccine production facilities in place
or manufacturing technology transfer/local production initiatives
underway.
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.4. Reprioritizing seasonal vaccination
The 2009 A(H1N1) pandemic has resulted in a renewed focus
n the burden imposed by inﬂuenza and the policies required to
imit its effect on public health. Reviews conducted by national
overnments and international health organizations have exam-
ned the response to the pandemic and, in a number of cases, to
easonal inﬂuenza. In particular, WHO  is updating its position on
easonal inﬂuenza vaccination, based on experience gained dur-
ng the A(H1N1) pandemic, further information from developing
ations, and expanded recommendations in some industrialized
ountries [14,15].
This  period of reﬂection provides an opportunity for countries
o reassess their prioritization of seasonal inﬂuenza vaccination,
nformed by new insights into the relative effectiveness of policy
easures at their disposal. IFPMA IVS aims to support this process
y providing periodic updates to its unique dataset of global vac-
ine provision, which will enable policy makers to monitor national
ptake, review progress towards coverage targets and assess the
mpact of local immunization initiatives.
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